B. infantis administration to humans selectively promotes immunoregulatory responses, suggesting that this microbe may have therapeutic utility in patients with inflammatory disease. Cross-talk between multiple pattern-recognition receptors and metabolic pathways determines the innate and subsequent T regulatory cell response to B. infantis.
These findings link nutrition, microbiota and the induction of tolerance within the gastrointestinal mucosa.
2012-02-06
Eng.
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland.
Gut. 2012 Mar;61(3):354-66
© Galenicom 1999-2013